US : FDA approves a third new weight-loss pill

The US Food and Drug Administration (FDA) has approved the combination of bupropion/naltrexone, developed by Orexigen Therapeutics, to be known as Contrave, for the treatment of obesity. Contrave's maker had hoped for approval three years ago, but ... Read Full Story